

Rossella Bruno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9558221/publications.pdf>

Version: 2024-02-01

38
papers

622
citations

623734

14
h-index

610901

24
g-index

38
all docs

38
docs citations

38
times ranked

1199
citing authors

#	ARTICLE	IF	CITATIONS
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2023, 76, 47-52.	2.0	9
2	Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation. <i>Frontiers in Oncology</i> , 2021, 11, 674604.	2.8	2
3	Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series. <i>Diagnostics</i> , 2021, 11, 1046.	2.6	4
4	Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3828.	3.7	6
5	Conventional Transbronchial Needle Aspiration (cTBNA) and EBUS-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Retrospective Study on the Comparison of the Two Methods for Diagnostic Adequacy in Molecular Analysis. <i>Journal of Molecular Pathology</i> , 2021, 2, 296-305.	1.2	2
6	Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review. <i>Diagnostics</i> , 2020, 10, 521.	2.6	83
7	Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 457-466.	2.8	7
8	Crizotinib in ROS1 and MET Deregulated NSCLC Response. <i>Clinical Cancer Research</i> , 2020, 26, 1775-1775.	7.0	2
9	A gene expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. <i>Oncology Letters</i> , 2020, 19, 1060-1065.	1.8	3
10	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7312-7319.	7.0	139
11	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. <i>Scientific Reports</i> , 2019, 9, 3536.	3.3	11
12	Pathological Diagnosis of Mesothelioma. , 2019, , 99-122.		0
13	Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 480-489.	2.5	33
14	Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, S342-S352.	1.4	23
15	The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. <i>Journal of Thoracic Disease</i> , 2018, 10, S276-S284.	1.4	39
16	Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes. <i>Lung Cancer</i> , 2018, 124, 95-101.	2.0	29
17	Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature. <i>Scientific Reports</i> , 2018, 8, 10623.	3.3	25
18	Maternal Uniparental Disomy 14 (Temple Syndrome) as a Result of a Robertsonian Translocation. <i>Molecular Syndromology</i> , 2017, 8, 131-138.	0.8	16

#	ARTICLE	IF	CITATIONS
19	P3.02a-010 Evaluation of Aberrant ALK Expression in Lung Cancer by RT-PCR and Comparison with FISH and Immunohistochemistry. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1165-S1166.	1.1	0
20	P3.02b-027 Detection of EGFR Mutations in Plasma of Lung Adenocarcinoma Patients Using Real-Time PCR and Mass Spectrometry. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1202-S1203.	1.1	0
21	P3.02b-034 Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1207.	1.1	0
22	P3.03-024 Malignant Pleural Mesothelioma: Gene Expression Profiling of the Main Histological Subtypes. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1358-S1359.	1.1	0
23	P1.02-077 Whole-Transcriptome Gene Expression Analysis of Pulmonary Sarcomatoid Carcinomas. <i>Journal of Thoracic Oncology</i> , 2017, 12, S535.	1.1	0
24	Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. <i>Oncology Letters</i> , 2017, 14, 5947-5951.	1.8	16
25	Novel prognostic markers for epithelioid malignant pleural mesothelioma. <i>Journal of Clinical Oncology</i> , 2017, 35, e20028-e20028.	1.6	3
26	MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations. <i>Journal of Clinical Oncology</i> , 2017, 35, e20656-e20656.	1.6	1
27	Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. <i>Oncotarget</i> , 2017, 8, 2758-2770.	1.8	26
28	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. <i>Oncology Reports</i> , 2016, 36, 1166-1172.	2.6	15
29	Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. <i>Oncology Letters</i> , 2016, 12, 4009-4012.	1.8	15
30	Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction. <i>Molecular Medicine Reports</i> , 2016, 14, 2238-2242.	2.4	1
31	A 17q duplication prenatally detected. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2015, 54, 326-329.	1.3	0
32	625â€kb microduplication at Xp22.12 including RPS6KA3 in a child with mild intellectual disability. <i>Journal of Human Genetics</i> , 2015, 60, 777-780.	2.3	7
33	A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. <i>Mutation Research - Reviews in Mutation Research</i> , 2012, 750, 132-140.	5.5	45
34	Two Novel Polymorphisms in 5' Flanking Region of the Mesothelin Gene are Associated with Soluble Mesothelin-Related Peptide (SMRP) Levels. <i>International Journal of Biological Markers</i> , 2011, 26, 117-123.	1.8	13
35	Soluble markers for diagnosis of malignant pleural mesothelioma. <i>Biomarkers in Medicine</i> , 2011, 5, 261-273.	1.4	21
36	Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. <i>Occupational and Environmental Medicine</i> , 2010, 67, 233-236.	2.8	19

#	ARTICLE	IF	CITATIONS
37	Medullary Thyroid Cancer: New Targeted Molecular Therapies. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2010, 4, 10-14.	0.6	4
38	Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review. Precision Cancer Medicine, 0, 4, 14-14.	1.8	3